New monoclonal antibody selectively targets PCa sites

December 1, 2001

New York-A newer monoclonal antibody is showing a canny ability to target prostate cancer cells in both bony and soft tissue, and its therapeutic potential is now undergoing testing. Neil Bander, MD, and colleagues from New York Presbyterian-Weill Cornell Medical Center developed the antibody, dubbed J591 (licensed by BZL Biologics, Inc., Framingham, MA, and sub-licensed by Millennium Pharmaceuticals, Cambridge, MA).